Back to News
Market Impact: 0.25
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
The company amended existing warrants to align their trigger event with anticipated FDA approval of its CGuard Prime 80 cm device. Management continues to expect approval in Q4 2026, creating a potentially positive regulatory catalyst, though approval remains prospective.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Perpetual underdog AMD nips at Nvidia's heels as it joins the $1T club
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Meta's Muse personal AI agent tops ChatGPT, Grok and Claude for post-launch downloads
- Muse, Meta's extraordinarily privileged AI assistant, has a serious 0-day
- Ra Capital Management sells $21.8m in Sionna Therapeutics shares
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production